Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors

Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors

US Patent 11192955 · Granted Dec 7, 2021

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Systems and methods for hemoclip deployment2025
Tool for hemostasis and tissue approximation2025
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and de2025
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and de2025
Antibody-drug conjugates and uses thereof2025
Antibody-drug conjugates and uses thereof2025
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and de2025
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and de2025
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and de2023
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and de2023
Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy2022
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PAR2022